Management of patients on bisphosphonates and prevention of bisphosphonate-related osteonecrosis of the jaw.
Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a recent discovery and has only been brought to the attention of health care professionals in since 2003. The purpose of this article is to describe this phenomenon and focus on preventive strategies to minimize the risk of patients developing this condition. Management and prevention will be broken down into patients taking IV bisphosphonates and patients taking oral bisphosphonates.
Chu
Victor
V
D000284:Administration, Oral; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003646:Debridement; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007571:Jaw Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008875:Middle Aged; D019647:Oral Surgical Procedures / Q000009:adverse effects*; D010020:Osteonecrosis / Q000139:chemically induced / Q000517:prevention & control*; D010024:Osteoporosis / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates